Skip to main content
Shandong Boan Biotechnology Co., Ltd. logo

Shandong Boan Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 6955 ISIN · CNE100005RV4 HKEX Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6955

About Shandong Boan Biotechnology Co., Ltd.

http://www.boan-bio.com

Shandong Boan Biotechnology Co., Ltd. is a fully integrated biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of biologics. Established in 2013, the company focuses on therapeutic antibodies and biosimilars, targeting key therapeutic areas such as oncology, autoimmune, ophthalmic, and metabolic diseases.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.
Regulatory Filings Classification · 87% confidence The document is a voluntary announcement made to the Hong Kong stock exchange, detailing the submission of a Biologics License Application (BLA) to the U.S. FDA for two biosimilar products. It contains no financial statements, earnings data, or formal report attachments, and it is not an annual/interim report, earnings release, or other specific form type. It is a miscellaneous regulatory announcement and thus falls under the general Regulatory Filings category.
2026-05-29 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 22 JUNE 2026 (APPLICABLE TO HOLDERS OF H SHARES)
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a FORM OF PROXY for use at the company’s Annual General Meeting, providing shareholders with voting instructions and appointment of proxies. This falls squarely under Proxy Solicitation & Information Statement materials, as it is circulated to request votes and provide information for the AGM.
2026-05-27 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal Notice of Annual General Meeting, setting out the date, agenda (ordinary and special resolutions), and proxy voting instructions. It is sent to shareholders to provide information about the meeting and solicit their votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI), rather than an AGM presentation or a general regulatory announcement.
2026-05-27 English
(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a shareholder circular containing the letter from the board, explanatory statements, and the notice of the Annual General Meeting with proposed resolutions on the 2025 annual report, board reports, auditor reappointment, director remuneration, general mandates, share repurchase and adoption of an incentive scheme. It is a proxy solicitation/information statement for the AGM, not the report itself. Therefore, it falls under Proxy Solicitation & Information Statement (PSI).
2026-05-27 English
VOLUNTARY ANNOUNCEMENT BOLUOJIA (DENOSUMAB INJECTION) NEWLY APPROVED IN CHINA FOR TREATING BONE METASTASES FROM SOLID TUMORS AND MULTIPLE MYELOMA
Regulatory Filings Classification · 90% confidence The document is a voluntary operational update (product approval announcement) filed on the Hong Kong Exchange, providing business news about a new drug indication. It contains no financial statements, no meeting materials, no share transactions, no dividend or M&A information. It is not the full annual or quarterly report and does not include substantive financial data. Therefore it does not match any specific financial report category and falls into the general regulatory announcement / miscellaneous filings category (RNS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE
Transaction in Own Shares Classification · 96% confidence The document is a voluntary announcement by Shandong Boan Biotechnology regarding its plan to repurchase its own shares on the open market under an existing repurchase mandate. This clearly falls under “Transaction in Own Shares” (share repurchase) rather than a financing update, board change, or report publication. Accordingly, the correct classification is POS.
2026-05-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.